Şunu aradınız:: namr (Hırvatça - İngilizce)

namr ima antiepileptičko djelovanje, ali je u životinjskim modelima napadaja manje potentan od retigabina.
namr has antiepileptic activity, but is less potent than retigabine in animal seizure models.

pokazalo se da se hemodijalizom može smanjiti koncentracija retigabina i namr u plazmi za oko 50%.
haemodialysis has been shown to reduce the plasma concentrations of retigabine and namr by approximately 50%.

uz to, retigabin i namr u ljudskim primarnim hepatocitima nisu inducirali cyp1a2 ili cyp3a4/5.
in addition, retigabine and namr did not induce cyp1a2 or cyp3a4/5 in human primary hepatocytes.

stoga nije vjerojatno da bi istovremena primjena s inhibitorima ili induktorima enzima citokrom p450 utjecala na farmakokinetiku retigabina ili namr-a.
therefore, co-administration with inhibitors or inducers of cytochrome p450 enzymes is unlikely to affect the pharmacokinetics of retigabine or namr.

retigabin se metabolizira i u n-acetil metabolit (namr) koji se također kasnije glukuronidira.
retigabine is also metabolised to an n-acetyl metabolite (namr) that is also subsequently glucuronidated.

podaci dobiveni iz in vitro ispitivanja pokazali su da n-acetil metabolit retigabina (namr) inhibira prijenos digoksina posredovan p-glikoproteinom ovisno o koncentraciji.
data from an in vitro study showed that the n-acetyl metabolite of retigabine (namr) inhibited p-glycoprotein-mediated transport of digoxin in a concentration-dependent manner.